Brief: Epigenomics FY 2016 total revenue up by 102 pct to 4.2 mln euros

Epigenomics AG

26/04/2017 03:56

April 26 (Reuters) - Epigenomics Ag  ECXn.DE  
    * Says in 2016, Epigenomics' total revenue increased by 102 
percent to 4.2 million euros 
    * Epigenomics - "level of 2016 product revenue was impacted 
by initial stocking effects from our commercialization partner 
post FDA approval" 
    * Says expects 2017 revenue to be broadly consistent with 
our 2016 product and licensing revenue 
    * Says expect EBITDA before share-based payment expenses for 
2017 to be at a lower level than in 2016 
    * Says a range from EUR -12.0 to -13.5 million is assumed 
for 2017 EBITDA before share-based payment expenses 
    * Says based on business plan for 2017, we expect cash 
consumption in line with EBITDA guidance 
    * Says "beyond 2017, we may raise additional capital in 
2017" 
 
Source text for Eikon:  ID:nEQ8pmkDr  
Further company coverage:  ECXn.DE  
 
 ((Bangalore.newsroom@thomsonreuters.com;))